MiR-210 is a prognostic marker in clear cell renal cell carcinoma

Journal of Molecular Diagnostics

Volumn 17, Issue 2, 2015, Pages 136-144

  Samaan, Sara ^a,b   Khella, Heba W Z ^a,b   Girgis, Andrew ^a,b   Scorilas, Andreas ^c   Lianidou, Evi ^c   Gabril, Manal ^d   Krylov, Sergey N ^e   Jewett, Michael ^f,g   Bjarnason, Georg A ^h   El Said, Hala ⁱ   Yousef, George M ^a,b,g  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF ATHENS   (Greece)

^d LONDON HEALTH SCIENCES CENTRE   (Canada)

^e YORK UNIVERSITY   (Canada)

^f PRINCESS MARGARET HOSPITAL   (Canada)

^g UNIVERSITY OF TORONTO   (Canada)

^h DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

ⁱ MENOUFIA UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MICRORNA 210; VASCULOTROPIN A; MICRORNA; MIRN210 MICRORNA, HUMAN; TUMOR MARKER;

AGED; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; ONCOCYTOMA; OVERALL SURVIVAL; PATHOGENESIS; PROGNOSTIC ASSESSMENT; UPREGULATION; GENETICS; IN VITRO STUDY; KIDNEY TUMOR; PATHOLOGY; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BIOMARKERS, TUMOR; CARCINOMA, RENAL CELL; FEMALE; HUMANS; IN VITRO TECHNIQUES; KIDNEY NEOPLASMS; MALE; MICRORNAS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84922663313     PISSN: 15251578     EISSN: 19437811     Source Type: Journal    
DOI: 10.1016/j.jmoldx.2014.10.005     Document Type: Article

References (53)

1. W.H. Chow, S.S. Devesa, J.L. Warren, and J.F. Fraumeni Jr. Rising incidence of renal cell cancer in the United States JAMA 281 1999 1628 1631
2. M. Murai, and M. Oya Renal cell carcinoma: etiology, incidence and epidemiology Curr Opin Urol 14 2004 229 233
3. A.M. Meloni-Ehrig Renal cancer: cytogenetic and molecular genetic aspects Am J Med Genet 115 2002 164 172
4. Y.M. Youssef, N.M. White, J. Grigull, A. Krizova, C. Samy, S. Mejia-Guerrero, A. Evans, and G.M. Yousef Accurate molecular classification of kidney cancer subtypes using microRNA signature Eur Urol 59 2011 721 730
5. J.D. Gordan, P. Lal, V.R. Dondeti, R. Letrero, K.N. Parekh, C.E. Oquendo, R.A. Greenberg, K.T. Flaherty, W.K. Rathmell, B. Keith, M.C. Simon, and K.L. Nathanson HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma Cancer Cell 14 2008 435 446
6. S. Pena-Llopis, S. Vega-Rubin-de-Celis, A. Liao, N. Leng, A. Pavia-Jimenez, S. Wang, T. Yamasaki, L. Zhrebker, S. Sivanand, P. Spence, L. Kinch, T. Hambuch, S. Jain, Y. Lotan, V. Margulis, A.I. Sagalowsky, P.B. Summerour, W. Kabbani, S.W. Wong, N. Grishin, M. Laurent, X.J. Xie, C.D. Haudenschild, M.T. Ross, D.R. Bentley, P. Kapur, and J. Brugarolas BAP1 loss defines a new class of renal cell carcinoma Nat Genet 44 2012 751 759
7. A.M. Molina, R.J. Motzer, and D.Y. Heng Systemic treatment options for untreated patients with metastatic clear cell renal cancer Semin Oncol 40 2013 436 443
8. D.Y. Heng, W. Xie, M.M. Regan, L.C. Harshman, G.A. Bjarnason, U.N. Vaishampayan, M. Mackenzie, L. Wood, F. Donskov, M.H. Tan, S.Y. Rha, N. Agarwal, C. Kollmannsberger, B.I. Rini, and T.K. Choueiri External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study Lancet Oncol 14 2013 141 148
9. A. Arsanious, G.A. Bjarnason, and G.M. Yousef From bench to bedside: current and future applications of molecular profiling in renal cell carcinoma Mol Cancer 8 2009 20
10. B. Delahunt, J.M. Kittelson, M.R. McCredie, A.E. Reeve, J.H. Stewart, and A.M. Bilous Prognostic importance of tumor size for localized conventional (clear cell) renal cell carcinoma: assessment of TNM T1 and T2 tumor categories and comparison with other prognostic parameters Cancer 94 2002 658 664
11. P. Guinan, L.H. Sobin, F. Algaba, F. Badellino, S. Kameyama, G. MacLennan, and A. Novick TNM staging of renal cell carcinoma: Workgroup No. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC) Cancer 80 1997 992 993
12. G. Kurban, C. Gedye, C. Morales, G.M. Yousef, A. Almatar, and M.A. Jewett Diagnosis and treatment of small renal masses: the role for molecular biology Arch Esp Urol 66 2013 505 516
13. T.F. Chow, Y.M. Youssef, E. Lianidou, A.D. Romaschin, R.J. Honey, R. Stewart, K.T. Pace, and G.M. Yousef Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis Clin Biochem 43 2009 150 158
14. M. Jung, H.J. Mollenkopf, C. Grimm, I. Wagner, M. Albrecht, T. Waller, C. Pilarsky, M. Johannsen, C. Stephan, H. Lehrach, W. Nietfeld, T. Rudel, K. Jung, and G. Kristiansen MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy J Cell Mol Med 13 2009 3918 3928
15. N.M. White, T.T. Bao, J. Grigull, Y.M. Youssef, A. Girgis, M. Diamandis, E. Fatoohi, M. Metias, R.J. Honey, R. Stewart, K.T. Pace, G.A. Bjarnason, and G.M. Yousef miRNA profiling for clear cell renal cell carcinoma: biomarker discovery and identification of potential controls and consequences of miRNA dysregulation J Urol 186 2011 1077 1083
16. H.E. Gee, C. Ivan, G.A. Calin, and M. Ivan HypoxamiRs and cancer: from biology to targeted therapy Antioxid Redox Signal 21 2014 1220 1238
17. S.M. Metias, E. Lianidou, and G.M. Yousef MicroRNAs in clinical oncology: at the crossroads between promises and problems J Clin Pathol 62 2009 771 776
18. M. Eilertsen, S. Andersen, S. Al-Saad, E. Richardsen, H. Stenvold, S.M. Hald, K. Al-Shibli, T. Donnem, L.T. Busund, and R.M. Bremnes Positive prognostic impact of miR-210 in non-small cell lung cancer Lung Cancer 83 2014 272 278
19. X. Huang, and J. Zuo Emerging roles of miR-210 and other non-coding RNAs in the hypoxic response Acta Biochim Biophys Sin (Shanghai) 46 2014 220 232
20. R.I. McCormick, C. Blick, J. Ragoussis, J. Schoedel, D.R. Mole, A.C. Young, P.J. Selby, R.E. Banks, and A.L. Harris miR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis Br J Cancer 108 2013 1133 1142
21. M. Redova, A. Poprach, A. Besse, R. Iliev, J. Nekvindova, R. Lakomy, L. Radova, M. Svoboda, J. Dolezel, R. Vyzula, and O. Slaby MiR-210 expression in tumor tissue and in vitro effects of its silencing in renal cell carcinoma Tumour Biol 34 2013 481 491
22. H.W. Khella, N.M. White, H. Faragalla, M. Gabril, M. Boazak, D. Dorian, B. Khalil, H. Antonios, T.T. Bao, M.D. Pasic, R.J. Honey, R. Stewart, K.T. Pace, G.A. Bjarnason, M.A. Jewett, and G.M. Yousef Exploring the role of miRNAs in renal cell carcinoma progression and metastasis through bioinformatic and experimental analyses Tumour Biol 33 2012 131 140
23. N.M. White, T.F. Chow, S. Mejia-Guerrero, M. Diamandis, Y. Rofael, H. Faragalla, M. Mankaruous, M. Gabril, A. Girgis, and G.M. Yousef Three dysregulated miRNAs control kallikrein 10 expression and cell proliferation in ovarian cancer Br J Cancer 102 2010 1244 1253
24. K.J. Livak, and T.D. Schmittgen Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method Methods 25 2001 402 408
25. Z. Wotschofsky, H.A. Meyer, M. Jung, A. Fendler, I. Wagner, C. Stephan, J. Busch, A. Erbersdobler, A.C. Disch, H.J. Mollenkopf, and K. Jung Reference genes for the relative quantification of microRNAs in renal cell carcinomas and their metastases Anal Biochem 417 2011 233 241
26. X. Huang, Q.T. Le, and A.J. Giaccia MiR-210-micromanager of the hypoxia pathway Trends Mol Med 16 2010 230 237
27. C.S. Neal, M.Z. Michael, L.H. Rawlings, M.B. Van der Hoek, and J.M. Gleadle The VHL-dependent regulation of microRNAs in renal cancer BMC Med 8 2010 64
28. C. Nakada, Y. Tsukamoto, K. Matsuura, T.L. Nguyen, N. Hijiya, T. Uchida, F. Sato, H. Mimata, M. Seto, and M. Moriyama Overexpression of miR-210, a downstream target of HIF1alpha, causes centrosome amplification in renal carcinoma cells J Pathol 224 2011 280 288
29. S. Osanto, Y. Qin, H.P. Buermans, J. Berkers, E. Lerut, J.J. Goeman, and H. van Poppel Genome-wide microRNA expression analysis of clear cell renal cell carcinoma by next generation deep sequencing PLoS One 7 2012 e38298
30. T.A. Baudino, and J.L. Cleveland The Max network gone mad Mol Cell Biol 21 2001 691 702
31. B.R. Lane, J. Li, M. Zhou, D. Babineau, P. Faber, A.C. Novick, and B.R. Williams Differential expression in clear cell renal cell carcinoma identified by gene expression profiling J Urol 181 2009 849 860
32. C. Livingstone IGF2 and cancer Endocr Relat Cancer 20 2013 R321 R339
33. S.W. Tang, W.H. Chang, Y.C. Su, Y.C. Chen, Y.H. Lai, P.T. Wu, C.I. Hsu, W.C. Lin, M.K. Lai, and J.Y. Lin MYC pathway is activated in clear cell renal cell carcinoma and essential for proliferation of clear cell renal cell carcinoma cells Cancer Lett 273 2009 35 43
34. D. Huang, Y. Ding, W.M. Luo, S. Bender, C.N. Qian, E. Kort, Z.F. Zhang, K. VandenBeldt, N.S. Duesbery, J.H. Resau, and B.T. Teh Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo Cancer Res 68 2008 81 88
35. H.W. Kim, H.K. Haider, S. Jiang, and M. Ashraf Ischemic preconditioning augments survival of stem cells via miR-210 expression by targeting caspase-8-associated protein 2 J Biol Chem 284 2009 33161 33168
36. M.E. Crosby, R. Kulshreshtha, M. Ivan, and P.M. Glazer MicroRNA regulation of DNA repair gene expression in hypoxic stress Cancer Res 69 2009 1221 1229
37. M. Sauermann, O. Sahin, H. Sultmann, F. Hahne, S. Blaszkiewicz, M. Majety, K. Zatloukal, L. Fuzesi, A. Poustka, S. Wiemann, and D. Arlt Reduced expression of vacuole membrane protein 1 affects the invasion capacity of tumor cells Oncogene 27 2008 1320 1326
38. S. Tsuchiya, T. Fujiwara, F. Sato, Y. Shimada, E. Tanaka, Y. Sakai, K. Shimizu, and G. Tsujimoto MicroRNA-210 regulates cancer cell proliferation through targeting fibroblast growth factor receptor-like 1 (FGFRL1) J Biol Chem 286 2011 420 428
39. H. Cai, L. Lin, H. Cai, M. Tang, and Z. Wang Prognostic evaluation of microRNA-210 expression in pediatric osteosarcoma Med Oncol 30 2013 499
40. M. Li, X. Ma, M. Li, B. Zhang, J. Huang, L. Liu, and Y. Wei Prognostic role of microRNA-210 in various carcinomas: a systematic review and meta-analysis Dis Markers 2014 2014 106197
41. A. Qu, L. Du, Y. Yang, H. Liu, J. Li, L. Wang, Y. Liu, Z. Dong, X. Zhang, X. Jiang, H. Wang, Z. Li, G. Zheng, and C. Wang Hypoxia-inducible MiR-210 is an independent prognostic factor and contributes to metastasis in colorectal cancer PLoS One 9 2014 e90952
42. M. Zhan, Y. Li, B. Hu, X. He, J. Huang, Y. Zhao, S. Fu, and L. Lu Serum MicroRNA-210 as a Predictive Biomarker for Treatment Response and Prognosis in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization J Vasc Interv Radiol 25 2014 1279 1287.e1
43. J. Wang, J. Zhao, M. Shi, Y. Ding, H. Sun, F. Yuan, and Z. Zou Elevated expression of miR-210 predicts poor survival of cancer patients: a systematic review and meta-analysis PLoS One 9 2014 e89223
44. S. Durinck, E.W. Stawiski, A. Pavía-Jiménez, Z. Modrusan, P. Kapur, and B.S. Jaiswal Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes Nat Genet 47 2015 13 21
45. L. Ehsani, R. Seth, S. Bacopulos, A. Seth, and A.O. Osunkoya BCA2 is differentially expressed in renal oncocytoma: an analysis of 158 renal neoplasms Tumour Biol 34 2013 787 791
46. K.A. Furge, M.H. Tan, K. Dykema, E. Kort, W. Stadler, X. Yao, M. Zhou, and B.T. Teh Identification of deregulated oncogenic pathways in renal cell carcinoma: an integrated oncogenomic approach based on gene expression profiling Oncogene 26 2007 1346 1350
47. B. Shuch, S. Vourganti, J.C. Friend, L.M. Zehngebot, W.M. Linehan, and R. Srinivasan Targeting the mTOR pathway in Chromophobe Kidney Cancer J Cancer 3 2012 152 157
48. N.M. White, and G.M. Yousef MicroRNAs: exploring a new dimension in the pathogenesis of kidney cancer (editorial) BMC Med 8 2010 65
49. W.G. Kaelin Jr. Kidney cancer: now available in a new flavor Cancer Cell 14 2008 423 424
50. J. Dancey Genomics, personalized medicine and cancer practice Clin Biochem 45 2012 379 381
51. M.D. Pasic, S. Samaan, and G.M. Yousef Genomic medicine: new frontiers and new challenges Clin Chem 59 2013 158 167
52. G.M. Yousef Personalized cancer genomics: the road map to clinical implementation Clin Chem 58 2012 661 663
53. P. Maroto, and B. Rini Molecular biomarkers in advanced renal cell carcinoma Clin Cancer Res 20 2014 2060 2071